Publications

1. GVS advice on the re-assessment of vericiguat (Verquvo®) for the treatment of adults with chronic heart failure

   The National Health Care Institute has assessed whether the medicinal product vericiguat (Verquvo®) can be included in the ...

   Report | 12-05-2023

2. Advisory report on possible candidate for conditional inclusion of atidarsagene autotemcel (Libmeldy®)

   The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate atidarsagene autotemcel ...

   Report | 08-05-2023

3. Evaluation of orphan drugs arrangement eculizumab (Soliris®) for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS)

   The National Health Care Institute concludes that agreements made in 2016 about the use of the medicinal product eculizumab ...

   Letter | 08-05-2023

4. GVS advice on lanadelumab (Takhzyro®) for the prevention of recurrent attacks of hereditary angioedema (HAE)

   The National Health Care Institute has assessed whether the medicinal product lanadelumab (Takhzyro®) can be included in the ...

   Report | 28-04-2023

5. GVS advice on sacubitril/valsartan (Entresto®)

   At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute has carried out an ...

   Report | 28-04-2023

6. Package advice on the lock procedure medicinal product brexucabtagene autoleucel (Tecartus®) for the treatment of mantle cell lymphoma (MCL)

   The National Health Care Institute has assessed whether the medicinal product brexucabtagene autoleucel (Tecartus®) can be ...

   Report | 17-04-2023

7. GVS advice for the extension of the List 2 conditions for evolocumab (Repatha®) and alirocumab (Praluent®) for excessively high cholesterol

   The National Health Care Institute has assessed whether the PCSK9 inhibitors evolocumab (Repatha®) and alirocumab (Praluent®) can ...

   Report | 17-04-2023

8. GVS advice on mifepristone (Mifegyne®) for the treatment of miscarriages

   The National Health Care Institute has tested whether mifepristone (Mifegyne®) can be included in the Medicine Reimbursement ...

   Report | 08-03-2023

9. Conditional inclusion of orphan drugs, conditionals and exceptionals (progress report for 2022)

   At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...

   Report | 01-03-2023

10. Package advice on the lock procedure medicinal product trastuzumab-deruxtecan (Enhertu®) for the treatment of HER2-positive breast cancer

    The National Health Care Institute has assessed whether the medicinal product trastuzumab-deruxtecan (Enhertu®) can be reimbursed ...

    Publication | 15-02-2023